Gapping down
In reaction to disappointing earnings/guidance: N/A.
M&A news:
In reaction to disappointing earnings/guidance: N/A.
M&A news:
- CYH -2.4% (confirms it is exploring a variety of options with financial sponsors, as well as other potential alternativesg)
Other news:
- VICL -18.7% (Vical and Astellas (ALPMY) announce topline results from a randomized, double-blind, placebo-controlled Phase 2 study evaluating the safety and efficacy of cytomegalovirus)
- CVRR -13.3% (still checking, stock moved aggressively higher in final minutes of trading on Friday; may be attributed to that)
- ORMP -3% (still checking), DEPO -0.9% (confirms it received request to call special meeting of shareholders)
- TEVA -0.5% (announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease)
Analyst comments:
- OSUR -2.1% (downgraded to Neutral from Buy at BTIG Research)
- CALD -1.5% (downgraded to Sell from Neutral at Dougherty & Company)
- PYPL -1.1% (downgraded to Hold from Buy at Canaccord Genuity)